Not Signed In - Alteon's ALT-2074 Demonstrates Ability To Reduce Infarct Size By 80 Percent In Mice With Haptoglobin 2-2 Genotype
Tue, 14 Nov 2006 08:00 AM EST
... Alteon Inc. (Amex: ALT) announced today that data demonstrating the ability of its compound ALT-2074 (formerly BXT-51072 licensed from OXIS International, Inc., OTC Bulletin Board: OXIS. [click link for full article] ...
Related Topics
- ALT
- Dementia - Multi-Infarct
- Multi-Infarct Dementia
- Theophylline Tablets or Capsules
- Theophylline Oral Solution, Syrup, or Suspension
- AST
- Myocardial Infarct
- Myocardial Infarct Recovery
- Corticotropin Injection
- Portion Size
- Decreased ability to care for self
- Loss of ability to care for self
- Decreased ability to interact with others
- Decreased ability to walk
- Loss of ability to interact
- Loss of ability to interact with others
- Loss of ability to function or care for self
- Loss of voice and speaking ability
- Loss of ability to interact or function
- Decreased ability to work or care for self
email this page
print this page
bookmark this page
feedback on this page
